导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.18% | 2459/4773 |
| 近一周 | -2.57% | 4061/5465 |
| 近一月 | -7.04% | 4420/5421 |
| 近一季 | -14.18% | 4256/5231 |
| 近半年 | -2.59% | 2204/4920 |
| 近一年 | 1.94% | 2383/4394 |
| 近两年 | 60.20% | 1235/2954 |
| 近三年 | 31.08% | 1051/2253 |
| 成立以来 | 32.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.71% 2440/4961 |
21.79% 1155/5312 |
- - |
- - |
| 2025 | 26.56% 1621/4813 |
-0.79% 2409/3635 |
-0.74% 3014/4076 |
31.37% 1125/4524 |
-2.18% 3104/4813 |
| 2024 | 12.49% 1241/3463 |
0.37% 990/2808 |
-3.50% 1384/3014 |
20.11% 756/3129 |
-3.31% 2322/3463 |
| 2023 | -15.95% 1667/2656 |
4.29% 995/2280 |
-6.18% 1600/2385 |
-7.52% 1586/2515 |
-7.12% 2058/2655 |
| 2022 | -25.01% 1282/2207 |
-18.69% 1378/1919 |
8.72% 331/2016 |
-16.64% 1484/2113 |
1.76% 1154/2208 |
| 2021 | -1.24% 789/1822 |
-5.04% 904/1255 |
10.33% 475/1330 |
-8.32% 1126/1466 |
2.82% 511/1822 |
| 2020 | 46.23% 212/1250 |
-7.43% 543/1028 |
21.85% 220/1067 |
10.04% 595/1164 |
17.82% 111/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 工银瑞信深证100ETF VS. 长安沪深300非周期A(740101) |